Personalised medicine in head and neck cancers

Speaker: Jean-Pascal Machiels

J-P Machiels underlines the importance of the EGFR target in head & neck cancer, as monoclonal antibodies against the EGFR target improve outcome. However, a limitation with anti-EGFR therapy exists, as a minority of patients will have objective response and the issue in head & neck cancer, compared to other cancers, is that there are no predictive biomarkers. He goes on to discuss the differences, at the molecular level, between HPV-positive and negative disease.

Discussion Points

  • What does the latest research suggest about the EGFR signalling pathway as a therapeutic target in head and neck Squamous cell carcinoma?
  • Outline of the role of signalling pathways (Ras/Raf/Mek/Erk and PTEN/PI3K/Akt) and Predictive markers for cetuximab in head and neck cancer
  • What does the latest research suggest about the molecular basis and clinical outcome of human papillomavirus (HPV)-positive head and neck squamous cell carcinoma?
  • What is the role of anti-EGFR targeted therapy for HPV-positive head and neck squamous cell carcinoma?
  • Where do we stand with immunotherapy research in head and neck cancers?